logo BDSP

Base documentaire


  1. Incremental cost-effectiveness of incorporating oestriol evaluation in down syndrome screening programmes.

    Article - En anglais

    As screening for Down syndrome becomes increasingly sophisticated, it is important to evaluate the newer technologies in terms of their cost-effectiveness.

    One recent addition to Down syndrome screening programmes is maternal serum unconjugated oestriol (uE3), especially when used in conjunction with maternal serum a-fetoprotein and human chorionic gonadotropin.

    Using assumptions used in a California proposal to justify an expanded screening programme for Down syndrome, we calculated both the average and the incremental cost-effectiveness of adding uE3.

    Mots-clés Pascal : Mongolisme, Homme, Chromosome G21, Trisomie, Aneuploïdie, Aberration chromosomique, Dépistage, Diagnostic, Prénatal, Aspect économique, Exploration hormonale, Analyse biochimique, Oestriol, Technique, Programme sanitaire, Californie, Etats Unis, Amérique du Nord, Amérique, Oestrogène, Hormone stéroïde sexuelle, Hormone ovarienne

    Mots-clés Pascal anglais : Down syndrome, Human, G21-Chromosome, Trisomy, Aneuploidy, Chromosomal aberration, Medical screening, Diagnosis, Prenatal, Economic aspect, Hormonal investigation, Biochemical analysis, Estriol, Technique, Sanitary program, California, United States, North America, America, Estrogen, Sex steroid hormone, Ovarian hormone

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 94-0581306

    Code Inist : 002B20F01. Création : 09/06/1995.